Neumora Therapeutics Inc [NMRA] stock is trading at $10.85, up 3.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The NMRA shares have gain 5.14% over the last week, with a monthly amount glided 10.83%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on November 05, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $15 from $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on October 01, 2024, and set its price target to $30. On July 22, 2024, Needham initiated with a Buy rating and assigned a price target of $23 on the stock. Mizuho started tracking the stock assigning a Outperform rating and suggested a price target of $20 on July 08, 2024. Deutsche Bank initiated its recommendation with a Hold and recommended $13 as its price target on December 12, 2023. William Blair started tracking with a Outperform rating for this stock on October 10, 2023, and assigned it a price target of $26. In a note dated October 10, 2023, Stifel initiated an Buy rating and provided a target price of $26 on this stock.
Neumora Therapeutics Inc [NMRA] stock has fluctuated between $8.33 and $21.00 over the past year. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $10.85 at the most recent close of the market. An investor can expect a potential return of 98.16% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -0.74 and Total Capital is -0.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.25 points at the first support level, and at 9.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.28, and for the 2nd resistance point, it is at 11.70.
Ratios To Look Out For
For context, Neumora Therapeutics Inc’s Current Ratio is 10.98. On the other hand, the Quick Ratio is 10.98, and the Cash Ratio is 8.69.
Transactions by insiders
Recent insider trading involved Fust Matthew K, Director, that happened on Oct 18 ’24 when 14049.0 shares were sold. Director, Fust Matthew K completed a deal on Oct 17 ’24 to sell 7739.0 shares. Meanwhile, Director Fust Matthew K bought 14049.0 shares on Oct 18 ’24.
